论文部分内容阅读
近来用干扰素α—2b和人白细胞干扰素治疗基底细胞癌(BCC)均获得成功。干扰素—γ是一种强免疫调节剂,但它对BCC的治疗潜力尚不明确。作者研究了小剂量重组干扰素—γ(rIFN—γ)对BCC的疗效和副作用。研究对象为7例未经治疗的结节型BCC患者,其中1例结节伴有溃疡,自愿接受rIFN—γ治疗。选择出现rIFN—γ副作用最小的用药剂量和给药途径。每一皮损内每周注射2次,共4周,总量为1.6×10~6IU(2×10~5IU×8剂量)。治疗过程中检测治疗反应,并随访8周。
Recently, the treatment of basal cell carcinoma (BCC) with interferon alpha-2b and human leukocyte interferon has been successful. Interferon-gamma is a potent immunomodulator, but its therapeutic potential for BCC remains unclear. The authors studied the efficacy and side effects of low-dose recombinant interferon-gamma (rIFN-[gamma]) on BCC. The subjects were 7 untreated nodular BCC patients, 1 of whom had nodules with ulcers and were voluntarily treated with rIFN-γ. The dose and route of administration with minimal side effects of rIFN-gamma were selected. Each lesion was injected twice a week for 4 weeks and the total amount was 1.6 × 10 ~ 6 IU (2 × 10 ~ 5IU × 8 doses). Treatment response was measured during treatment and followed up for 8 weeks.